Successful Immunotherapy for Rare Lung Cancer
Author Information
Author(s): Inukai-Motokura Yumi, Ninomiya Kiichiro, Baba Takahiro, Omori Hiroki, Takeguchi Tetsuya, Uno Mari, Ayada Yoshiyuki, Tanaka Takehiro, Maeda Yoshinobu, Ohashi Kadoaki
Primary Institution: Okayama University Hospital
Hypothesis
Can combination immunotherapy with ipilimumab and nivolumab effectively treat metastatic pulmonary sclerosing pneumocytoma?
Conclusion
The combination of ipilimumab and nivolumab showed a significant positive response in a patient with metastatic pulmonary sclerosing pneumocytoma.
Supporting Evidence
- The patient had a significant response to immunotherapy after previous treatments failed.
- This is the first reported case of successful treatment of multiple distant metastatic PSP with ipilimumab and nivolumab.
- Genetic analysis identified an AKT1 E17K mutation, characteristic of PSP.
- The tumor showed absence of PD-L1 expression.
Takeaway
A woman with a rare lung cancer called pulmonary sclerosing pneumocytoma got better after taking two special medicines together.
Methodology
The patient received combination therapy with ipilimumab and nivolumab after previous treatments failed.
Limitations
The study is based on a single case, and the treatment duration may not be sufficient to fully assess efficacy.
Participant Demographics
A 48-year-old female with a 21 pack-year smoking history.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website